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Background
One century ago human African try-
panosomiasis (HAT), also known as sleep-
ing sickness, was believed to curb the
development of colonial territories. As
soon as the cause of the disease was clearly
identified, colonial authorities established
extensive control operations, fearing an
unpopulated continent and a shortage of
human labour to exploit natural resources.
Systematic screening, treatment, and
patient follow-up was established in west-
ern and central Africa for the gambiense
form of the disease while, animal reservoir
and vector control was mainly implement-
ed in eastern and southern Africa for the
rhodesiense form.
By the 1960s, transmission was practi-
cally interrupted in all endemic areas,
providing evidence that the elimination of
the disease as a public health problem was
feasible and could be achieved with basic
tools. Thereafter, the rarity of cases led to
a loss of interest in sustained surveillance,
and the risk of re-emergence of the disease
was overlooked. Thus in the 1980s the
disease re-emerged. By the 1990s, flare-
ups were observed throughout past en-
demic areas, leading to a worrisome
increase in the number of reported cases.
At this time, nongovernmental organiza-
tions (NGOs) played a crucial role in the
control of HAT. However, their interven-
tions were mainly focused on remote and
insecure areas. As emergency operators,
their policy understandably excluded sup-
port to National Sleeping Sickness Control
Programmes (NSSCPs), which resulted in
(i) the establishment of substitute HAT
control systems (ii), the maintenance of a
large part of the population at risk out of
the umbrella of NGO projects, and (iii) the
difficulty for national programmes to
sustain control achievements after the
NGOs’ withdrawal. Concurrently, bilater-
al cooperation continued to support
NSSCPs in some historically linked coun-
tries.
Concerning HAT screening, the card
agglutination trypanosomiasis test (CATT)
for serological screening of populations at
risk of HAT gambiense was developed
during the 1970s [1], but its large-scale
production encountered many problems,
hindering its availability [2]; in addition,
production of anti-trypanosomal drugs
was seriously threatened due to the lower
economic return for manufacturers.
Research for new diagnostic tools and
drugs was scarce [3]. Only eflornithine,
initially developed for cancer treatment,
was finally registered for the treatment
of the gambiense form of the disease in
1990 [4]. But its cost and complex
distribution and administration require-
ments made it inappropriate for the
under-equipped peripheral health ser-
vices in remote rural areas where HAT
was prevalent. Only some well-funded
NGOs were able to afford the cost of
eflornithine treatment.
During the 1990s, security constraints
due to civil wars and social upheavals
complicated HAT control by preventing
access to a large number of HAT-endemic
areas, leading to difficulties in reaching a
large number of affected populations and
consequently to a considerable lack of
epidemiological information. The World
Health Organization (WHO) Expert
Committee on HAT Control and Surveil-
lance held in 1995, in consideration of the
huge uncertainties between the reported
cases and the factual field situation,
estimated that the true number of cases
was at least 10 times more than reported.
Thus from the 30,000 reported cases
annually, it was estimated that some
300,000 infected individuals remained
ignored in the field [5].
In 1997, the 50th World Health Assem-
bly expressed its concerns about the major
recrudescence of cases by adopting a
resolution to raise awareness and national
and international interest [6].
Subsequently, WHO enhanced its co-
ordinating role and promoted networking
with partners, developing a strong advo-
cacy and awareness campaign. As a result,
the private sector recognized its responsi-
bility, which led Aventis Pharma and
Bayer Health Care to grant in 2001 and
2002 a substantial support to WHO for
the control and surveillance of HAT. This
support included HAT drug donation and
financial contributions that allowed WHO
to strengthen its support to disease-
endemic countries (DECs).
The importance of the various compo-
nents of the epidemiology of trypanosomi-
asis (human, animal, vector control, agri-
cultural activity, and livestock production)
and their impact on the development of
rural Africa led WHO, in 1995, to
promote together with the Food and
Agriculture Organization (FAO), the In-
ternational Atomic Energy Agency
(IAEA), and the African Union InterAfri-
can Bureau for Animal Resources (AU-
IBAR), an inter-sectoral initiative that
ultimately became, in 1997, the Pro-
gramme Against African Trypanosomiasis
(PAAT, http://www.fao.org/ag/againfo/
programmes/en/paat/disease.html).
In parallel, African heads of state and
governments established during the Afri-
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Pan African Tsetse and Trypanosomiasis
Eradication Campaign (PATTEC, http://
www.africa-union.org/Structure_of_the_
Commission/depPattec.htm) with the ob-
jective to render Africa a tsetse- and
trypanosomiasis-free continent.
Current Situation
Between 2000 and 2009, out of 36
countries listed as endemic, 24 received
the exclusive support of WHO either to
assess the epidemiological status of HAT or
to establish control and surveillance activ-
ities (Benin, Burkina Faso, Cameroon,
Chad, Co ˆte d’Ivoire, Gabon, Ghana,
Guinea, Guinea Bissau, Kenya, Liberia,
Malawi, Mali, Mozambique, Nigeria,
Rwanda, Senegal, Sierra Leone, Swazi-
land, Togo, Uganda, United Republic of
Tanzania, Zambia, and Zimbabwe); six
received support from WHO as well as
NGOs or through bilateral cooperation
(Angola, Central African Republic [CAR],
Congo, Democratic Republic of the Congo
[DRC], Equatorial Guinea, and Sudan);
and finally, six countries, Botswana, Bur-
undi, Ethiopia, Gambia, Namibia, and
Niger, which are listed as endemic but not
having reported any cases in the last 20
years, have not received any support yet.
The 30 countries mentioned above
received WHO support in the form of
i) Technical assistance. It is provided
either by WHO staff or by WHO
temporary advisers.
ii) Access to diagnosis. This support
includes the equipment, reagents,
logistics, and funds to allow the
national teams to reach HAT
transmission areas to perform ac-
tive case-finding surveys and set up
passive surveillance.
iii) Training. As part of capacity build-
ing, targeted at two technical levels;
(a) training on site, hands on (410
technical staff from 23 disease-
endemic countries were trained);
(b) participation in the Internation-
al Course on African Trypanoso-
moses implemented in collabora-
tion with the Association against
Trypanosomiasis in Africa (105
programme managers or scientists
from 22 countries have participated
in either one of the five courses).
iv) Access to treatment. This covers the
provision of drugs as well as patient
accessibility. During the last decade,
WHO has covered the need of
DECs by distributing, in collabora-
tion with Me ´decins sans Frontie `res
(MSF)-Logistics, 594,200 vials of
melarsoprol, 576,375 vials of pent-
amidine, 477,542 vials of eflor-
nithine, and 13,597 vials of suramin.
One main objective of WHO in the ‘‘access
to treatment’’ initiative was to reduce the use
of the arsenic derivative melarsoprol for the
treatment of second stage gambiense cases by
making eflornithine, actually the sole alter-
native to melarsoprol, accessible. Indeed,
during the period 2003–2006, despite the
availability of eflornithine and the known
toxicity of melarsoprol, the latter remained
widely used and 88% of the second stage
gambiense cases were treated with this drug
(Figure 1). Only well-funded NGOs could
afford the costly and complex use of
eflornithine as first line treatment, while
NSSCPs used eflornithine exclusively to
treat melarsoprol relapses. This was dem-
onstrated during the period 2003–2006 by a
ratio of eflornithine distribution of 9 to 1 to
NGOs versus NSSCPs (Figure 2).
In 2006, a number of DECs requested
the support of WHO to train their staff on
the use of eflornithine and requested the
provision of the necessary equipment to
switch gradually from melarsoprol to
eflornithine as first line treatment. Subse-
quently, a training of trainers was orga-
nized in Southern Sudan and a kit
containing the drugs as well as all the
materials needed to administer two full
eflornithine treatments was designed by
WHO and distributed with the collabora-
tion of MSF-Logistics [7]. The kit for two
eflornithine treatments weighted 40 kg at
a cost of US$1,420. This particular effort
Figure 1. Percentage of second stage T. b. gambiense patients treated according to drug used. Eflornithine versus melarsoprol (2003–
2009).
doi:10.1371/journal.pntd.0001007.g001
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DECs to regularly decrease their use of
melarsoprol and increase the use of
eflornithine for the treatment of second
stage gambiense cases. Consequently, in
2009, a 57% reduction in the use of
melarsoprol was recorded. Indeed, the
percentage of patients treated with this
drug fell from 88% to 38% (Figure 1), and
subsequently the use of eflornithine by
NSSCPs versus NGOs increased by 250%
(from 20% to 70%) (Figure 2).
Nifurtimox, registered for Chagas dis-
ease, showed efficacy during compassion-
ate use in melarsoprol refractory cases
[8,9]. In order to simplify the eflornithine
schedule, attempts were made to demon-
strate that a therapy combining nifurtimox
and eflornithine could contribute to a
simpler administration of the drugs; some
trials took place in DRC during the late
1990s [10] and in Uganda during the early
2000s [11,12].
In 2003, an extensive nifurtimox/eflor-
nithine combination treatment (NECT)
clinical trial started in Congo and later in
DRC involving MSF, Epicentre, the
Special Programme for Research & Train-
ing in Tropical Diseases (TDR), and
Drugs for Neglected Diseases initiative
(DNDi). The trial ended in 2008. Results
indicated that NECT presented no inferi-
or efficacy and safety than the eflornithine
monotherapy [13].
Following the inclusion of the NECT on
the WHO Essential Medicines List in May
2009 [14], NSSCPs requested WHO to
train their staff in order to incorporate this
new combination in their national policy.
A training for trainers was organized in
Kinshasa in November 2009 for French
speaking countries and another for English
speaking countries in Uganda in February
2010 [15].
Thereafter, a new kit for NECT treat-
ment was designed. Thanks to the reduc-
tion of drug quantity and materials, using
the same packaging form as for the
eflornithine monotherapy treatment kits,
a new kit for four full NECT treatments
weighting 36 kg at a cost of US$1,440 was
produced. This kit has already been
distributed to nine countries (reporting
together 96% of all Trypanosoma brucei
gambiense cases in 2009): Cameroon,
CAR, Chad, Co ˆte d’Ivoire, DRC, Equa-
torial Guinea, Gabon, Sudan, and
Uganda.
However, NECT does not change the
paradigm of HAT treatment since it
remains logistically complicated to imple-
ment. Nevertheless, it is anticipated that
NECT will contribute to sustain the
already observed decreasing trend of
melarsoprol use for the treatment of
second stage T. b. gambiense infections [16].
During the period 2006–2009, WHO
promoted research for better knowledge of
HAT epidemiology and for the develop-
ment of new tools. With that objective in
mind, 23 agreements for ‘‘performance of
work’’ were concluded with research
institutions of 11 countries (Belgium,
Burkina Faso, Democratic Republic of
the Congo, France, Germany, Italy,
Kenya, Malawi, Uganda, United King-
dom and the United Republic of Tanza-
nia).
In 2006, WHO and the Foundation for
Innovative New Diagnostics (FIND,
http://www.finddiagnostics.org/) signed
a 5-year Memorandum of Understanding
to promote the development of simple and
more sensitive and specific diagnostic tests.
WHO took the responsibility to set up a
specimen bank to facilitate the evaluation
of relevant new diagnostic tools and to
reduce the need for field trials. Currently,
samples from 1,700 people including
patients, seropositive-suspects, and con-
trols have been collected from 14 sites in
DRC, Guinea, Chad, Uganda, Malawi,
and United Republic of Tanzania. More
than 20,000 samples (including serum,
plasma, white blood cells, urine, saliva,
and CSF) are stored in the central
repository bank at the Institut Pasteur in
Paris.
Strong collaboration has been estab-
lished with groups working on the devel-
opment of new drugs, mainly the Consor-
tium for Parasitic Drug Development
(CPDD, http://www.unc.edu/~jonessk/)
and DNDi (http://www.dndi.org/).
In addition, the Division of Parasitic
Diseases of the National Center for
Infectious Diseases, Centers for Disease
Control and Prevention in Atlanta, United
Figure 2. Institutional rate use of eflornithine. National Sleeping Sickness Control Programmes versus nongovernmental organizations (2003–
2009).
doi:10.1371/journal.pntd.0001007.g002
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the Institute of Tropical Medicine (ITM)
in Antwerp, Belgium, and the Research
Unit of the Institut de Recherche pour le
De ´veloppement (IRD) based in the Inter-
national Centre for Research and Devel-
opment in Livestock in Sub Humid Areas
in Bobo-Diulaso, Burkina Faso (CIRDES),
have been nominated as WHO Collabo-
rating Centres.
In February 2008, WHO launched the
Atlas of HAT initiative to map all reported
cases for the period 2000–2009 at the
village level. This initiative is jointly
implemented with FAO in the framework
of the PAAT. Presently, mapping includes
23 out the 25 countries having reported at
least one case in the last 10 years. In the
two remaining countries, Angola and
DRC, data processing is ongoing. The
Atlas database also includes epidemiolog-
ical information that can be used by
NSSCPs, NGOs, and research institutions
to monitor and evaluate the impact of
control activities, to assess epidemiological
trends, and to plan control or research
activities [17].
As a consequence of these activities, the
number of new cases reported to WHO in
2009 has dropped below 10,000 for the
first time in 50 years [18]. It represents a
decrease of 63% since 2000 (Figure 3). In
2009, only two countries have reported
more than 1,000 new cases, namely CAR
and DRC representing, respectively, 11%
and 73% of the total cases reported. One
country, Chad, has reported more than
500 but less than 1,000 new cases. Three
countries (Angola, Sudan, and Uganda)
have reported more than 100 but less than
500 new cases. Eleven countries have
reported less than 100 cases: Cameroon,
Congo, Co ˆte d’Ivoire, Equatorial Guinea,
Gabon, Guinea, Kenya, Malawi, United
Republic of Tanzania, Zambia, and Zim-
babwe.
Finally, 19 countries listed as being
HAT endemic reported no cases in 2009.
Seven of these have performed HAT
surveillance activities: Benin, Burkina
Faso, Ghana, Mali, Nigeria, Sierra Leone,
and Togo. Nine have no regular surveil-
lance activities but have reported no cases
for decades. These include Burundi,
Ethiopia, Gambia, Guinea Bissau, Liberia,
Mozambique, Niger, Rwanda, and Sene-
gal; however, these latter countries deserve
an assessment to clarify their epidemiolog-
ical situation. Two countries, namely
Botswana and Namibia, are considered
disease transmission free due to the
recently implemented, successful tsetse
elimination campaigns [19,20]. Finally,
Swaziland has been shown through an
extensive tsetse survey to harbour Glossina
austeni, which has been never described as
a HAT vector [21] (Figure 4).
Discussion
During the last decade, the WHO
public private partnership (PPP) estab-
lished in 2001 with Aventis Pharma and
renewed in 2006 by sanofi-aventis has
made possible to carry out extensive HAT
control activities and to strengthen the
capacities of NSSCPs. The PPP has been
complemented by bilateral cooperation,
NGOs, research institutes, and Bayer
AG’s support. Furthermore, the cessation
of civil wars and social upheavals has also
substantially facilitated access to HAT-
endemic areas.
In 2009, the number of new cases of
HAT reported to WHO has dropped
below the symbolic number of 10,000,
while in the period 2000–2009 the number
of people screened increased due to the
greater number of health care facilities
involved in passive screening and the
improvement of the performance of active
case-finding surveys. Due to the improved
knowledge of HAT distribution, WHO
estimated in 2006 the factor gap between
cases reported and cases infected to be
three [22] instead of ten, as was thought in
1995 [5].
Considering the next steps to be imple-
mented, it is important to note that the
disease situation is not homogeneous
throughout the continent.
The gambiense form of the disease has in
several foci already reached a prevalence
threshold compatible with the concept
‘‘eliminated as a public health problem’’.
To consolidate such results, and ensure
sustainability, an adapted control and sur-
veillance approach will have to be imple-
mented within the national health system.
WhereasinotherfociHATremainsapublic
health issue, it is mostly due to accessibility
Figure 3. Evolution of reported cases of both forms of human African trypanosomiasis (1998–2009).
doi:10.1371/journal.pntd.0001007.g003
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fore, reinforced control measures must be
maintained using the classical vertical ap-
proaches with the participation of existing
health care structures.
The rhodesiense form of HAT is a
zoonotic disease involving cattle and game
in the transmission cycle. Cattle move-
ment is a continuous threat of disease
transmission as well as spread and subse-
quently a source of outbreaks [24].
Furthermore, wildlife in protected areas
are niches for contamination; there is a
continuous risk for park rangers, the
surrounding population, and visitors to
become infected. Controlling this form of
the disease requires a multisectoral ap-
proach. Therefore, it is crucial to reinforce
local health care capacities for diagnosis
and disease management as well as to
establish effective coordination with veter-
inary and natural resources management
services in charge of domestic animals,
wild animals, and vector control.
Despite encouraging results and exciting
perspectives, the process remains fragile.
At this stage, some obstacles are anticipat-
ed in the course of future control activities
and a few issues should be carefully
considered. These are mainly:
N The decline on contribution by NGOs
and bilateral cooperation towards
HAT control. During the period
2000–2009 there were nine bilateral
and 38 NGO HAT projects, while in
2010 there remained only one bilateral
(DRC) and five NGO projects (CAR,
DRC, Sudan, and Uganda). The
Figure 4. Classification of human African trypanosomiasis-endemic countries according to cases reported in 2009.
doi:10.1371/journal.pntd.0001007.g004
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decrease in HAT-related emergencies
and the substantial improvement of
country self-managed HAT control
activities.
N The "tyranny of disability adjusted life
years (DALYs)’’ expresses the lack of
interest of donors when the burden of
the disease is decreasing. Then, sup-
porting institutions not only withdraw
from HAT control but also from HAT
research. With the reduced amount of
funds available for control, it seems
obvious that the responsibility to give
‘‘the last strike to the dying beast’’ will
exclusively rely on the overloaded and
weak national health services. Also, the
loss of support for research will
definitely eliminate any hope to get
the needed, so long awaited new tools,
not only to accelerate the current
control process but also to boost the
involvement of health services in HAT
surveillance and control in order to
sustain the achieved results. Such a
situation will likely open the door for
the re-emergence of the disease.
N While the control of cattle as a HAT
reservoir appears to be a reachable
objective that would in turn allow the
control of T. b. rhodesiense infections in
affected areas [25], the control of the
disease in wildlife and the vector in
protected areas and game reserves
could be more complicated due to
conservationist, ecological, and envi-
ronmental considerations.
Furthermore, close monitoring is needed
to assess the impact of climate changes and
demographic evolution [26,27] in HAT
transmission.
Conclusion
By the end of the last century, WHO
and its partners had developed a strong
and successful advocacy programme to
secure access to diagnosis and treatment,
ensuring availability of funds and drugs to
support DECs. As a result, during the first
decade of the current century, great
advances have been made in HAT
control.
In 2007, a WHO informal consultation
of the heads of NSSCPs held in Geneva
reached the conclusion that elimination of
the disease as a public health problem was
possible [28]. This conclusion was based
on the achievements obtained, on the
current understanding of the epidemiology
of the disease, and on the willingness of
African heads of states and governments to
eradicate tsetse and trypanosomiasis as
stated when the PATTEC was established
in 2000.
The time has now come to sensitize
stakeholders on the pertinence and ethical
duty of embarking on the process of
eliminating HAT as a public health
problem despite the difficulties, obstacles,
and threats that are expected in this
process. Without such hammering ap-
proach, there is a risk of stagnation in
control and surveillance as occurred in the
late 1960s that ultimately led to the return
of the disease.
Today, WHO and its partners are
committed to reinforcing and coordinating
actions towards a sustainable elimination
process [29]. While there are still technical
aspects to be solved, the elimination of
HAT as a public health problem will
require social peace, institutional support,
and adequate funding for its implementa-
tion. These last conditions are not exclu-
sive to the control, elimination, and
sustained surveillance of HAT but also
for the overall development of DECs,
which would contribute to the control of
HAT as well.
When targeting the elimination of HAT
as a public health problem, the goal should
be recognized as a major achievement but
must never be considered as an end point.
Without appropriate discrimination, the
use of the word ‘‘elimination’’ may lead to
risky conclusions. The disease believed to
‘‘no longer exist’’ will reach oblivion,
placing in the background the required
pressing efforts for a sustained and effec-
tive surveillance. It must be kept in mind
that "elimination" is not synonymous with
‘‘eradication’’. Elimination is only a point
in time in the control process of the
disease, at which stage the classical vertical
control intervention approaches are no
longer cost effective. Thus, the national
health system must take the ownership of
sustaining elimination by integrating HAT
surveillance in their services while main-
taining the capacity to react rapidly
according to the analytical results of the
surveillance outcome.
Elimination should be considered as the
beginning of a new process involving new
actors. Therefore, elimination of HAT as a
public health problem will require contin-
uous efforts and innovative approaches.
There is no doubt that new tools would
facilitate the elimination process and the
sustainability of results; thus, funding
efforts for HAT control and research must
continue based on public health objectives,
and no longer on the burden of the
disease.
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